Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome
Open Access
- 11 December 2014
- journal article
- research article
- Published by Springer Nature in European Journal of Medical Research
- Vol. 19 (1) , 1-7
Abstract
Gliomas are the most common human brain tumors. Glioblastoma, also known as glioblastoma multiform (GBM), is the most aggressive, malignant, and lethal glioma. The investigation of prognostic and diagnostic molecular biomarkers in glioma patients to provide direction on clinical practice is urgent. Recent studies demonstrated that abnormal DNA methylation states play a key role in the pathogenesis of this kind of tumor. In this study, we want to identify a novel biomarker related to glioma initiation and find the role of the glioma-related gene. We performed a methylation-specific microarray on the promoter region to identify methylation gene(s) that may affect outcome of GBM patients. Normal and GBM tissues were collected from Tiantan Hospital. Genomic DNA was extracted from these tissues and analyzed with a DNA promoter methylation microarray. Testis derived transcript (TES) protein expression was analyzed by immunohistochemistry in paraffin-embedded patient tissues. Western blotting was used to detect TES protein expression in the GBM cell line U251 with or without 5-aza-dC treatment. Cell apoptosis was evaluated by flow cytometry analysis using Annexin V/PI staining. We found that the TES promoter was hypermethylated in GBM compared to normal brain tissues under DNA promoter methylation microarray analysis. The GBM patients with TES hypermethylation had a short overall survival (P P TES promoter hypermethylation and down-regulated protein expression significantly correlated with worse patient outcome. Treatment on the GBM cell line (U251) with 5-aza-dC can highly release TES expression resulting in significant apoptosis in these cells. Our findings suggest that the TES gene is a novel tumor suppressor gene and might represent a valuable prognostic marker for glioblastoma, indicating a potential target for future GBM therapy.Keywords
This publication has 32 references indexed in Scilit:
- Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasivenessHuman Molecular Genetics, 2012
- Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor geneInternational Journal of Cancer, 2004
- Characterisation of chicken TES and its role in cell spreading and motilityCell Motility, 2004
- TES is a novel focal adhesion protein with a role in cell spreadingJournal of Cell Science, 2003
- The TES gene at 7q31.1 is methylated in tumours and encodes a novel growth-suppressing LIM domain proteinOncogene, 2001
- Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.2000
- CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.1996
- The retinoblastoma gene is involved in malignant progression of astrocytomasAnnals of Neurology, 1994
- Astrocytic Gliomas: Characterization on a Molecular Genetic Basis1994
- TP53 Gene Mutations and 17p Deletions in Human AstrocytomasGenes, Chromosomes and Cancer, 1991